Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSX:TH - Post Discussion
Theratechnologies Inc
> Now this could be interesting!
New Post
View:
Discussion
List
(43)
•••
SPCEO1
X
View Profile
View Bullboard History
Post by
SPCEO1
on Jul 08, 2022 8:58pm
Now this could be interesting!
Saw this on Twitter:
Nicole Saphier, MD
@NBSaphierMD
A few antivirals available by prescription when given early that can help prevent/lessen viral illness: Valtrex, Tamiflu,
Trogarzo
,Lagevrio. Yet, the FDA is allowing Paxlovid, one of the least studied antivirals, be given without an Rx. Pfizer must have a friend at the FDA.
8:51 PM · Jul 8, 2022
·
Twitter for iPhone
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on Jul 08, 2022 10:20pm
https://nhia.org/wp-content/uploads/2021/10/SUPPLEMENT-Nutrition-Covid-HIV1-Sept-Oct.2021-FINAL-1.pdf
(258)
•••
qwerty22
X
View Profile
View Bullboard History
Comment by
qwerty22
on Jul 09, 2022 8:47am
I'm thinking of calling this BS. I'm pretty sure we'd know if there had been a Trogarzo/coronavirus study. I can't find evidence of one. She isn't privy to some secret database of data. Best I can come up with is she's mixed up Trogarzo with CYDY's antibody which has been extensively studied against Covid (with meh results). CYDY's antibody isn't on her list.
...more
(43)
•••
SPCEO1
X
View Profile
View Bullboard History
Comment by
SPCEO1
on Jul 09, 2022 11:15am
I cannot see how anything will come of it but you never know. I was quite surprised to even see Trogarzo mentioned in the context of covid. Saphier is an actual doctor and also plays one on TV (she is a Fox News contributor). I have no idea how she pulled Trogarzo out of thin air to add to the mix of drugs she referred to here. Maybe someone on Reddit will pick up on it and send a horde of
...more
(7)
•••
jeffm34
X
View Profile
View Bullboard History
Comment by
jeffm34
on Jul 09, 2022 3:44pm
https://www.nature.com/articles/s41587-020-00791-6 Trogarzo is mentioned in this article as an antiviral mAb that has been approved but not as a mAb being looked at for treatment of coronaviruses "The use of antibodies as antivirals is gaining momentum. In the 20 years after Synagis (palivizumab) was approved for use against respiratory syncytial virus (RSV), no other mAbs targeting
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income